Luke Halpern, Assistant Editor

The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients.

Intravenous immunoglobulin (IVIG) treatment for dermatologic conditions shows effectiveness but poses risks of kidney decline and thromboembolism, necessitating careful monitoring.

A rehabilitation method commonly used in patients who experience a traumatic brain injury was found to improve symptoms of long COVID, including brain fog and measures of daily living.

A panel of health care experts at Asembia’s AXS25 Summit discussed the critical need for improved patient education and resources to help navigate complex financial assistance programs and health care plans.

The Inflation Reduction Act of 2022 (IRA) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and health care delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.

As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.

At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

Integrating community pharmacists into specialty pharmacy care can enhance patient access, address physician shortages, and expand pharmacists' roles in delivering high-quality clinical services, according to experts at Asembia’s AXS25 Summit.

New research confirms hydroxyurea's long-term effectiveness in reducing hospital visits for children with sickle cell anemia, supporting its use as standard treatment.

Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements.

The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.

A significant number of patients with high low-density lipoprotein (LDL) cholesterol lack prescribed lipid-lowering medications, highlighting gaps in treatment and care practices.

NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.

A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.

New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.

The announcement could ease the burden of prior authorizations on patients, which can cause unnecessary delays for patients receiving prescriptions and serious complications.

Invasive pneumococcal disease trends have fluctuated greatly over the past 2 decades, with older adults remaining at the center of disease burden.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.

These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.

Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.

Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.

Lepodisiran, a small interfering RNA, demonstrated cholesterol-lowering effects at 16-mg, 96-mg, and 400-mg doses, with the highest dose being the most effective.

Although the rate of coronary artery lesions decreased across both cohorts of this trial of children with Kawasaki disease, there were no differences in lesion reduction between those receiving intravenous immunoglobulin (IVIG) alone and those receiving IVIG with aspirin.

With a more direct mechanism of action against viral replication compared with standard treatments, the small interfering RNA (siRNA)-based MIR 19 treatment could revolutionize outpatient COVID-19 treatment.

Some patients with aplastic anemia treated with CK0801 achieved durable transfusion independence lasting over 3 years.

Patients who received a pneumococcal 13-valent conjugate vaccination had slightly lower incidence of severe COVID-19 outcomes, but the directions of these associations were mixed.

The new indication expands administration methods for the combination of efgartigimod alfa and hyaluronidase-qvfc, which are already approved for the treatment of some immune-related conditions.

When used in combination with background statin therapy, AZD0780 resulted in major reductions in low-density lipoprotein cholesterol (LDL-C) and achievements of guideline-recommended LDL-C goals.